Developer of an enterprise pharmacy platform designed to change the way prescription drugs are priced and patients are s
Developer of an enterprise pharmacy platform designed to change the way prescription drugs are priced and patients are serviced.
Other Healthcare Technology Systems📍 New York, NYFounded 2017
Current Valuation
$3.3B
as of 2025-Q3
UNICORN
QL Price
$3.5B
+7% vs last round
QuantLogix's current estimate for Judi Health, published 2026-09-27 — above the last disclosed round of $3.3B (2025-Q3).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$3.3B
2025-Q3
weight 0.5
Secondary market print
$3.6B
2026-06-27
weight 0.58
How this price has held up
No round has priced for Judi Health since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Judi Health, 2026-09-27 (f753ae1d1ba931d5).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Judi Health going public?
No. Judi Health is private and has not filed to go public. There is no S-1 on file.
What is Judi Health's valuation in 2026?
Judi Health is valued at $3.3B as of 2025-Q3, set by its Series F ($400M, Sep 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Judi Health filed an S-1?
No public S-1 is on file for Judi Health.
How much has Judi Health raised?
Judi Health has raised $762M in total, most recently a Series F of $400M in Sep 2025.
Is Judi Health publicly traded — can you buy Judi Health stock?
No. Judi Health is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Judi Health on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
New York, NY
Employees
1,097
Total Raised
$762M
Last Round
Series F — $400M (Sep 2025)
IPO Status
private
Fundraising Status
Series F · $400M · 1y ago
privateTotal raised $762M
Secondary Market
Implied price / share
$15.12
Last round price / share
$13.49
vs last round
+12.1%
Open interest
2
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series F
$400M
Sep 2025
—
$3.3B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Judi Health — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
+21% vs 2026-08
Open roles
128
via greenhouse
Product-build share
41%
engineering, research, product, design
Trajectory
expanding
balanced build + GTM — 41% builders vs 59% go-to-market/G&A — scaling both sides.
No tracked executive churn; open roles trending up.
Counted from Judi Health's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
PharmaceuticalMedicalHealth Care
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q3. Refreshed quarterly.